| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/19/2008 | US20080146523 Imidazole derivatives |
| 06/19/2008 | US20080146522 Inflammation, allergic diseases, metastatic cancers, pathogen infections; glycosaminoglycan related molecules |
| 06/19/2008 | US20080146521 Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
| 06/19/2008 | US20080146520 Animal feeds containing polyols |
| 06/19/2008 | US20080146519 IL-14alpha RNA inhibitors and antibodies to IL-14alpha for treatment of autoimmune diseases and lymphomas |
| 06/19/2008 | US20080146517 Indole Antiviral Compositions And Methods |
| 06/19/2008 | US20080146516 Cosmetic glycosaminoglycan synthesis stimulators; treating keratin materials; combating skin aging and/or drying out |
| 06/19/2008 | US20080146515 Canagliflozin, a sodium-glucose transporter 2 inhibitor as antiobesity, antidiabetic agent; purity; handling characteristics; easy formulation; storage stability |
| 06/19/2008 | US20080146514 Method and compositions for improving pulmonary hypertension |
| 06/19/2008 | US20080146509 delivery agent, parathyroid hormone, and calcitonin. This composition exhibits increased delivery of parathyroid hormone and/or calcitonin and is useful for the treatment of osteoporosis. The composition also permits simultaneous oral delivery of parathyroid hormone and calcitonin |
| 06/19/2008 | US20080146507 Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor |
| 06/19/2008 | US20080146506 Methods of Suppressing Microglial Activation |
| 06/19/2008 | US20080146505 47 Human Secreted Proteins |
| 06/19/2008 | US20080146502 method for modulating the sensation of satiety perception and to agents useful for same. Such agents are useful in modulating, controlling or otherwise affecting inter alia obesity, anorexia, weight maintenance, metabolic energy levels and/or inflammatory conditions in a subject |
| 06/19/2008 | US20080146495 methods for inhibiting the ability of HIV genes products to bind to the cytoplasmic domain of a CD4 receptor. This domain is necessary to the ability of the HIV Nef and Vpu gene products to connect the CD4 receptor to cellular degradation pathways. |
| 06/19/2008 | US20080146489 Treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well. |
| 06/19/2008 | US20080146472 Viscous liquid with mucosa moistening; for delivering medication, skin moisturizing and to enhances sexual experiences; comprising linseed and a seed polysaccharide extract soluble in water, a pH buffer (citric acid), and preservative for prevention of growth of micro-organisms and stability |
| 06/19/2008 | US20080146458 Process for the preparation of oxazolidinones and method of use thereof |
| 06/19/2008 | US20080145935 Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| 06/19/2008 | US20080145902 transphosphatidylation of fish liver phosphatidylcholine and L-serine, using phospholipases |
| 06/19/2008 | US20080145859 Diagnosis and treatment of cancer |
| 06/19/2008 | US20080145849 Methods for diagnosing and treating neuroendocrine cancer |
| 06/19/2008 | US20080145462 Compositions and methods for treating parasitic infections |
| 06/19/2008 | US20080145458 Administering extractsTribulus terrestris, Epimedium koreanum, Cinnamon cassia |
| 06/19/2008 | US20080145457 Administering saponins to an animal |
| 06/19/2008 | US20080145456 Aethereum gerani, Aethereum rosmarini, Aethereum citri, Mentholum, and ethylene-diamine-tetra-acetic acid-alkali metal salt (EDTA); eliminating pain of different locomotor complaints of the body |
| 06/19/2008 | US20080145453 4-(piperimidine-2thione)phenyl derivatives; kinesin Eg5 inhibitor; anticarcinogenic agent; the aldehyde, the ketone and the thiourea are reacted together in the solid phase, grafted onto resin by esterification, and detached by hydrolysis |
| 06/19/2008 | US20080145452 Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
| 06/19/2008 | US20080145451 Composition for relieving discomfort |
| 06/19/2008 | US20080145450 Delivery or removal of metals from biological systems |
| 06/19/2008 | US20080145449 Thiol reactive agents as a therapeutic modality |
| 06/19/2008 | US20080145446 Multi-purpose hand and/or skin cleaner, sanitizer, drug delivery and exercise system |
| 06/19/2008 | US20080145443 Diaper rash composition and method |
| 06/19/2008 | US20080145441 Core of metal atoms of gold, silver or copper covalently linked to a carbohydrate group and to at least 20 ligands |
| 06/19/2008 | US20080145440 Cisplatin intercalated into the double-helical DNA; stably retains cisplatin and exhibits an excellent slow-release property |
| 06/19/2008 | US20080145439 Nanoparticle drug formulations |
| 06/19/2008 | US20080145438 Melting a drug in a molten miscible surfactant; heating the mixture; and cooling the mixture while continuously mixing under high; maximizing precipitation of drug particles coated with the surfactant and having a greater rate of dissolution than pure unprocessed drug |
| 06/19/2008 | US20080145434 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use |
| 06/19/2008 | US20080145433 Darusentan oral dosage form |
| 06/19/2008 | US20080145430 With a surface stabilizer adsorbed on the surface; non-irritating and sufficiently bioavailable |
| 06/19/2008 | US20080145429 Dosage Form Containing Oxycodone and Naloxone |
| 06/19/2008 | US20080145428 Mascara Composition Containing Shape-Memory Polymers, Gels, and Fibers |
| 06/19/2008 | US20080145427 Dosage Forms Providing Controlled and Immediate Release of Cholesteryl Ester Transfer Protein Inhibitors and Immediate Release of Hmg-Coa Reductase Inhibitors |
| 06/19/2008 | US20080145425 Pharmaceutical composition of zolpidem |
| 06/19/2008 | US20080145424 Also including 0.5-5 % polyvinylpyrrolidone and 5-40 % hydroxypropyl methylcellulose; administering an endothelial nitric oxide synthase agonist (an HMG-CoA reductase inhibitor) and a NO precursor (L-arginine hydrochloride) for cerebrovascular/cardiovascular disorders; anticholesterol agents |
| 06/19/2008 | US20080145422 Galantamin, particularly galantaminehydrobromide, and carrier of a blend of lactose-based diluent and microcrystalline cellulose; excellent content uniformity and dissolution properties; adjuvants such as disintegrants, glidants, lubricants, and coating agents; direct compression; hardness of 20-40 kP |
| 06/19/2008 | US20080145421 Stabilized composition |
| 06/19/2008 | US20080145419 High viscosity liquid controlled delivery system and medical or surgical device |
| 06/19/2008 | US20080145418 Diindolylmethane for the treatment of HPV infection |
| 06/19/2008 | US20080145417 Pharmaceutical formulation for the efficient administration apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof |
| 06/19/2008 | US20080145416 Cross-linked ionic core micelles |
| 06/19/2008 | US20080145415 Bioresorbable Fillers Constituted by Phospholipid Liposomes and Hyaluronic Acid and/or the Derivatives Thereof |
| 06/19/2008 | US20080145413 Lipids and lipid assemblies comprising transfection enhancer elements |
| 06/19/2008 | US20080145411 Oxidized coenzyme Q10, a lysolecithin and an oil and fat where the weight ratio of the lysolecithin to the Q10 is >0.7: superior absorption; bioavailabiliry; stability; heat resistance; photostabiliy; food supplement; nutrients drugs; beverages; feet; pet food, cosmetics; nutraceuticals; soft capsules |
| 06/19/2008 | US20080145409 Composition for the treatment and prevention of peptic ulcer |
| 06/19/2008 | US20080145408 Soluble salts of Group Ia and 2a metal hydroxides; appetite suppression; weight loss; increase in fat metabolism rate; reduction in blood lipids and postprandial lipemia; increase the plasma level of (-)-hydroxycitric acid; bioavailability; dietetics; extracted from dried Garcinia rind |
| 06/19/2008 | US20080145407 Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid mmatrix of a two biodegradable polymer matrix |
| 06/19/2008 | US20080145406 Devices and methods for ophthalmic drug delivery |
| 06/19/2008 | US20080145403 Heating a mixture of cyclic lipid (bimatoprost) and a biodegradable polymer (polylactic acid) to 50-80 degrees C. and extruding; sustained release of the drug at >50 % of its potency;side effect reduction; amorphous drug forms; by-products inhibition; administering implants subconjunctivally |
| 06/19/2008 | US20080145402 Polymer coatings as carriers for the drug delivery of an hydroxyethylated ether derivative of rapamycin (A-179578) and another drug(s) such as an antiproliferative agent, anticoagulant, etc.; reduces restenosis in vasculature procedures to a level of 0-25%; coronary/periferal stents; grafts ; balloons |
| 06/19/2008 | US20080145386 TRPV1+ sensory neurons control of beta-cell stress and islet inflammation in diabetes |
| 06/19/2008 | US20080145381 Multi-subtype FIV vaccines |
| 06/19/2008 | US20080145377 G-CSF Polypeptides And Uses Thereof |
| 06/19/2008 | US20080145372 Bioreductively-Activated Prodrugs |
| 06/19/2008 | US20080145371 SYNTHESIS OF HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES |
| 06/19/2008 | US20080145370 Multimeric immunoglobulin for use in prevention and treatment of viral and microorganismal infection |
| 06/19/2008 | US20080145369 Using pc-cell-derived growth factor concentration as diagnostic indicator of cell proliferative disorders |
| 06/19/2008 | US20080145368 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 06/19/2008 | US20080145366 Platelet derived growth factor specific immunoglobulin for use in diagnosis, prevention and treatment of cell proliferative disorders; antisense agents; antitumor agents |
| 06/19/2008 | US20080145365 Human and mammalian stem cell-derived neuron survival factors |
| 06/19/2008 | US20080145362 Antibody combination useful for tumor therapy |
| 06/19/2008 | US20080145361 Uses of mammalian cytokine; related reagents |
| 06/19/2008 | US20080145359 Imaging, diagnosis and treatment of disease |
| 06/19/2008 | US20080145358 Method for Determining Responsiveness to Chk1 Inhibitors |
| 06/19/2008 | US20080145356 Administering glutenase to Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides |
| 06/19/2008 | US20080145351 Using protein kinase m-zeta inhibitor as therapeutic in treatment of alcohol addiction, post-traumatic disorder, and phobia |
| 06/19/2008 | US20080145339 Modified rolling circle initiator protein for use as therapeutic tool in suppression of viral replication and disorders |
| 06/19/2008 | US20080145336 Use of isoindol-1-one or 1,3-dione compounds for treating cancer, angiogenesis inhibition or phosphodiesterase-4 inhibition; use with various other biodrugs and drugs |
| 06/19/2008 | US20080145335 Which protect neural cells from degeneration and/or death in response to injury or disease; hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease |
| 06/19/2008 | US20080145334 Hepatitis c virus inhibitors |
| 06/19/2008 | US20080145322 picene (benzo[a,i]chrysene) carboxylic acid derivatives; bactericide; with other antimicrobial agent or antibiotic; prostatitis, biliary tract infections, urinary tract infections, cystitis, lung infections, sinus infections, ear infections, acne, rosacea, dental caries, periodontitis |
| 06/19/2008 | US20080145320 Antimicrobial compositions |
| 06/19/2008 | US20080145318 Atomoxetine agent may be any atomoxetine prodrug or metabolite that has been modified to alter rate at which drug is metabolized; such a modification may be accomplished, inter alia, by blocking phenoxy 4 position of atomoxetine agent; attention-deficit/hyperactivity disorders, asthma, allergies |
| 06/19/2008 | US20080145314 EGFR inhibitors promote axon regeneration |
| 06/19/2008 | US20080145313 Treatment of cancer by means of RNA interference; compositions comprise small interfering nucleic acid molecule that suppresses expression of target gene involved in energy metabolism pathway within tumor cell, in biosynthesis of nucleotides, in glycogen metabolism, in transport of sugars, amino acids |
| 06/19/2008 | US20080145311 Chelating agents with lipophilic carriers |
| 06/19/2008 | US20080142453 microbiocides comprising mixtures of dibromonitrilopropionamide and polyhexamethylene biguanide, used for controlling the growth of microorganisms in water |
| 06/19/2008 | DE102007043613A1 Medicament, useful for the treatment of Alzheimer's disease, comprises a pure biological alcohol, which is obtained from plants, preferably berries, fruits, herbs or its derivatives |
| 06/19/2008 | DE102006059319A1 Substituierte Aminofuranone und ihre Verwendung Substituted aminofuranones and their use |
| 06/19/2008 | DE102006059314A1 Preparing bromo-dimethyl-dihydro-indole, useful to prepare dimethyl-(trifluoromethyl)phenyl-dihydro-indol-ylsulfonyl-methylphen oxy acetic acid, comprises reacting dimethyl-dihydro-indol-ethanone with a brominating reagent and transforming |
| 06/19/2008 | DE102006058450A1 Zubereitungen zur Hemmung der Prostaglandin E2 Synthese Preparations for the inhibition of prostaglandin E2 synthesis |
| 06/19/2008 | DE102006058209A1 New triterpene type compounds comprising a pentacyclic basic unit of nor-oleanane- or nor-ursane-type, are 11-beta-hydroxysteroid dehydrogenase inhibitors, useful e.g. to treat and prevent diabetes, depression and glaucoma |
| 06/19/2008 | DE102006058207A1 New triterpene type compounds comprising a pentacyclic basic structure of nor-oleanan- or non-ursan -types are 11-beta-hydroxysteroid dehydrogenase inhibitors, useful e.g. to treat and prevent the diabetes, depression and glaucoma |
| 06/19/2008 | DE102006053475A1 Zubereitungen zur Hemmung der Prostaglandin E2 Synthese Preparations for the inhibition of prostaglandin E2 synthesis |
| 06/19/2008 | DE102006051088A1 Antioxidant, useful in the preparation of a dyeing agent, vesicle, carotenoid formulation, dermocosmetic, pharmaceutical, food, feed, gelatin capsule and/or solid- or liquid material, comprises an isorenieratene compound |
| 06/19/2008 | DE102004052877B4 Stabile wässrige Formulierungen eines Platin-Derivats A stable aqueous formulations of a platinum derivative |
| 06/19/2008 | DE10085149B4 Verfahren zur Herstellung von Acarbose mit hohem Reinheitsgrad A process for preparing acarbose with high purity |
| 06/19/2008 | CA2708006A1 Cancer chemoprevention strategy based on loss of imprinting of igf2 |
| 06/19/2008 | CA2678524A1 Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizon for treating or preventing diabetes mellitus and the use thereof |
| 06/19/2008 | CA2673111A1 Ph sensitive matrix formulation |